Novo Nordisk pays $1.3B for drug-coating tech to extend obesity treatment duration
Novo Nordisk has entered a $1.3 billion agreement with Swedish startup Nanexa for exclusive rights to its drug-coating technology. The deal covers up to five programs targeting obesity and diabetes, aiming to create longer-lasting injectable treatments.
The agreement gives Novo Nordisk access to Nanexa’s proprietary coating platform, which is designed to control how quickly injected drugs release in the body. By applying this technology to up to five obesity and diabetes programs, the Danish pharma giant aims to reduce dosing frequency, potentially improving patient adherence and convenience.
This move reflects a broader industry push toward extended-release formulations for chronic metabolic conditions. Longer-lasting injectables could ease the burden of frequent self-administration, though the deal’s success depends on clinical validation and regulatory approval across multiple candidates.
If the technology proves effective, patients managing obesity or diabetes may face fewer injections, simplifying daily routines and possibly improving long-term treatment consistency. Health systems could see reduced costs from better adherence, though pricing and access remain uncertain. The deal also signals growing competition in the weight-loss drug market, where durability of effect is a key differentiator. However, outcomes hinge on trial results and manufacturing scalability.